Melinta Therapeutics Obtains $70,000,000 Series C Round

  • Feed Type
  • Date
    2/10/2014
  • Company Name
    Melinta Therapeutics
  • Mailing Address
    300 George Street New Haven, CT 06511
  • Company Description
    Melinta Therapeutics’ mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.
  • Website
    http://www.melinta.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $70,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds from this financing will be used, in part, to advance delafloxacin, a differentiated fluoroquinolone, through an ongoing Phase 3 study of a single oral dose in individuals with uncomplicated gonorrhea, to the submission of a New Drug Application (NDA) in late 2014. In addition, the funds will support delafloxacin’s two ongoing Phase 3 trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and the selection of lead candidates from Melinta’s RX-04 research program.
  • M&A Terms
  • Venture Investor
    Vatera Healthcare Partners
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.